Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9346162 | 0.97 | CYP4F2 (0.42) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL12191374 | 0.97 | SMN1; SMN2 (0.40) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10557078 | 0.87 | CYP4F2 (0.39) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL14978154 | 0.84 | SMN1; SMN2 (0.44) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 | |
| 1,4-Butanediol SCHEMBL1318678 | 0.84 | SMN1; SMN2 (0.44) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL13130050 | 0.84 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL5931138 | 0.83 | SMN1; SMN2 (0.41) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10991502 | 0.83 | CYP4F2 (0.33) | CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL11040688 | 0.83 | CYP4F2 (0.33) | CYP4F2CYP4A11SMN1; SMN2ALDH1A1 | |
| SCHEMBL9345919 | 0.83 | LMNA (0.46) | CYP4F2CYP4A11SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180181002-A1 | METHOD OF PATTERN FORMATION AND METHOD OF PRODUCING POLYSILANE RESIN PRECURSOR | TOKYO OHKA KOGYO CO., LTD. (JP) | 2018-06-28 | — | — | US | disclosed |
| US-4521318-A | Lubricant compositions containing both hydrocarbyl substituted mono and bissuccinimide having polyamine chain linked hydroxacyl radicals, and neopentyl derivative | TEXACO INC. (US) | 1985-06-04 | — | — | US | disclosed |
| US-4194981-A | DISPERSNATS, DETERGENTS | TEXACO INC. (US) | 1980-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180181002-A1 | METHOD OF PATTERN FORMATION AND METHOD OF PRODUCING POLYSILANE RESIN PRECURSOR | RTN4, RER1, CROCC | CYP4F2 3169/4885CYP4A11 4420/4885SMN1; SMN2 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.